News | December 04, 2006

SCAI Abstract Deadline Extended

The Society for Cardiac Angiography and Interventions (SCAI) has extended the abstract deadline for its 30th Annual Scientific Sessions in Orlando, May 9-12, 2007. The new deadline is December 22, 2006 at midnight (EST).

The top three abstracts will received awards, and the top 10 abstracts selected will be featured for oral presentantion. All accepted abstracts will be published in the May 2007 edition of SCAI's Journal, “Catheterization and Cardiovascular Interventions.”

Abstract categories are:
-Acute Coronary Syndromes and Myocardial Infarction
-Adult Congenital
-Atherectomy/Plaque Modification
-Angiogenesis, Myogenesis, Cell Therapy and Gene Therapy
-Carotid Revascularization
-Complex PCI
-Contrast agents
-CTO
-Drug-Eluting Stents
-Endovascular & Peripheral Interventions (Excluding Neurovascular Intervention)
-Imaging: CT & MR
-Intravascular Imaging/Physiology
-Left Main & Multi-Vessel Intervention
-Interventions for Myocardial Infarction
-Miscellaneous
-Neurovascular, Carotid & Stroke Intervention
-Non-Invasive Imaging
-Pediatric
-Pharmacotherapy
-PTCA
-Restenosis
-Stents
-Thrombectomy and Distal Protection Devices
-Valvular Interventions
-Vascular Access & Arterial Closure Devices
-Vulnerable Plaque
-Women's Healthcare

For more information or to submit an abstract, visit www.scai.org.

Related Content

Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals | October 04, 2017
October 4, 2017 — MyoKardia Inc.
News | Pharmaceuticals | September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals | September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals | May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Feature | Pharmaceuticals | May 16, 2017
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal
Overlay Init